851
Participants
Start Date
April 24, 2014
Primary Completion Date
November 18, 2016
Study Completion Date
November 18, 2016
Chloroquine 600mg
600mg Chloroquine given to each subject on Day 1 and Day2 of the trial
Chloroquine 300mg
300mg Chloroquine given to each subject on Day 3 of the trial
Tafenoquine 50mg
single dose 50mg Tafenoquine given to subject on treatment arm 1 on Days 1 or 2
Tafenoquine 100mg
single dose 100mg Tafenoquine given to subject on treatment arm 2 on Days 1 or 2
Tafenoquine 300mg
single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2
Tafenoquine 600mg
single dose 600mg Tafenoquine given to subject on treatment arm 4 on Days 1 or 2
Primaquine 15mg
15mg Primaquine given once daily to subject on treatment arm 5 on Days 2 to 15.
Chloroquine 600mg (Part 2 )
600mg Chloroquine given to each subject on Day 1 and Day2 of the trial.
Chloroquine 300mg (Part 2 )
300mg Chloroquine given to each subject on Day 3 of the trial.
Tafenoquine 300mg (Part 2)
single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2.
Primaquine 15mg (Part2 )
15mg Primaquine given once daily to subject on treatment arm 3 on Days 2 to 15.
GSK Investigational Site, Rio Tuba, Bataraza
GSK Investigational Site, Bangkok
GSK Investigational Site, Tak
GSK Investigational Site, Lucknow
GSK Investigational Site, Chennai
GSK Investigational Site, Bāndarban
GSK Investigational Site, Oddar Meancheay Province
GSK Investigational Site, Gonder
GSK Investigational Site, Jimma
GSK Investigational Site, Bikaner
GSK Investigational Site, Manaus
GSK Investigational Site, Porto Velho
GSK Investigational Site, Secunderabad
GSK Investigational Site, Iquitos
Lead Sponsor
Medicines for Malaria Venture
OTHER
GlaxoSmithKline
INDUSTRY